[Table_StockNameRptType] 新凤鸣（603225） 公司点评 拟投资利夫生物，卡位生物基聚酯产业链 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-07-21 | | [收盘价（元） Table_BaseData] | 11.15 | | 近 12 个月最高/最低（元） | 14.78/9.59 | | 总股本（百万股） | 1,525 | | 流通股本（百万股） | 1,512 | | 流通股比例（%） | 99.16 | | 总市值（亿元） | 170 | | 流通市值（亿元） | 169 | [Table_Chart] 公司价格与沪深 300 走势比较 -40% -20% 0% 20% 40% 7/18 9/18 11/18 1/18 3/18 5/18 新凤鸣 沪深300 [Table_Author] 分析师：王强峰 [Table_Author] 分析师：王强峰 分析师：潘宁馨 执业证书号：S0010524070002 电话：13816562460 邮箱：pannx@hazq.com [Table_Compa ...

点评： 点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 公司发布《对外投资公告》，公司拟以人民币 1亿元增资 合肥利夫生物科技有限公司（以下简称 "利夫生 物"），增资后持有其7.0175%股权 。 风险提示： 下游需求不及预期，技术迭代风险，产品价格大幅波动风险。 发布日期： 2025-07-18 免责声明 拟投资利夫生物，迈向高端生物基纤维领域 公司在巩固和提升传统主业竞争力的同时，积极布局战略性新兴产业，拟投资利夫生物，迈向高端生物基 纤维领域。利夫生物作为全球范围内最早开始研究呋喃基材料的团队之一，专注于具有 "生物来源、环保 低碳、性能优异、应用广泛"特征的生物基呋喃材料的研发和生产。利夫生物的FDCA技术可赋能公司探索 以FDCA为基础的新材料（如PEF ...

2025 年 7 月 18 日 公司研究 拟投资利夫生物，迈向高端生物基纤维领域 ——新凤鸣（603225.SH）对外投资公告点评 要点 事件：公司发布《对外投资公告》，公司拟以人民币 1 亿元增资合肥利夫生物科 技有限公司（以下简称"利夫生物"），增资后持有其 7.0175%股权。 点评： 拟投资利夫生物，迈向高端生物基纤维领域：公司在巩固和提升传统主业竞争力 的同时，积极布局战略性新兴产业，拟投资利夫生物，迈向高端生物基纤维领域。 利夫生物作为全球范围内最早开始研究呋喃基材料的团队之一，专注于具有"生 物来源、环保低碳、性能优异、应用广泛"特征的生物基呋喃材料的研发和生产。 利夫生物的 FDCA 技术可赋能公司探索以 FDCA 为基础的新材料（如 PEF）在高 端生物基纤维、绿色包装等领域的应用前景与技术路径。 利夫生物是国内 FDCA 产业化领先者，未来发展可期：利夫生物是国内最早从事 FDCA 研发的团队和企业，生产的 FDCA 产品品质领先于同行。其已于 2022 年 建成投产全球首条 FDCA 千吨级产线以及百吨级连续流产线，预计 2025 年建成 投产全球第一条万吨级 FDCA 生产线，千吨线量 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the ongoing global biotechnology revolution, emphasizing its integration into economic and social development, addressing major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [1] - The Huazhong Securities Synthetic Biology Index, which includes 58 companies involved in synthetic biology and related technologies, decreased by 2.50% to 1484.292 during the week of June 30 to July 4, 2025, underperforming compared to the Shanghai Composite Index and the ChiNext Index [2][14] Summary by Sections 1.1 Secondary Market Performance - The synthetic biology sector experienced a decline of 2.50%, ranking 32nd among various sectors during the week of June 30 to July 4, 2025 [14] 1.2 Company Business Progress - Meihua Biological completed an overseas acquisition for HMO and high-end amino acid production, with a transaction value of approximately 8.33 billion yuan [21] - Weiyuan Biological's alolose sugar received approval as a new food ingredient, becoming the first company in China to produce it through fermentation technology [21] - Jinbo Biological secured a 3.4 billion yuan investment from Yangshengtang and Hangzhou Jiushi, enhancing its R&D capabilities in collagen technology [22] - Avantium signed a supply agreement for fully plant-based PEF packaging materials, emphasizing sustainability [24] - Syzygy Plasmonics announced the launch of a sustainable aviation fuel facility, aiming to produce over 350,000 gallons annually [24] 1.3 Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly a hundred firms completing new rounds of funding since the beginning of 2025. Zhejiang Rongrui Technology raised nearly 100 million yuan in a Pre-A round [27][28]

Core Viewpoint - The company plans to issue shares to specific investors through a simplified procedure, aiming to raise up to 226 million yuan for investment projects and working capital [1][2]. Group 1: Share Issuance Details - The share issuance will target no more than 35 specific investors, including legal entities and qualified foreign institutional investors [1]. - The issuance price will be no less than 80% of the average trading price over the 20 trading days prior to the pricing date [1]. - The total number of shares issued will not exceed 30% of the company's total share capital before the issuance [1]. Group 2: Fundraising and Investment Plans - The total amount to be raised is capped at 226 million yuan, which will be allocated to the construction of production projects and to supplement working capital [2]. - The investment projects include the construction of facilities for producing 2,000 tons of BPEF, 500 tons of BPF, and 1,000 tons of 9-fluorenone, with a total investment of approximately 19.42 million yuan [3]. Group 3: Company Ownership and Control - As of the announcement date, the company has a total of 325,468,375 shares, with the actual controller holding a combined 31.10% of the shares [2]. - The issuance is not expected to change the company's control, as the actual controller will still maintain a significant ownership stake post-issuance [2].

Core Viewpoint - The company plans to issue shares to specific investors, which may dilute immediate returns but aims to enhance long-term profitability and business expansion through increased capital [1][2][3] Financial Impact Analysis - After the issuance, the company's net asset scale will increase, but short-term net asset return may be affected, leading to potential dilution of immediate returns [1][3] - The estimated number of shares to be issued is 16,005,666, with the total amount of raised funds being an estimate and subject to regulatory approval [2] - Key financial metrics post-issuance include: - Total shares before issuance: 32,546.84 million shares; after issuance: 34,147.40 million shares - Net profit attributable to shareholders before issuance: 1,058.00 million yuan; after issuance: 846.40 million yuan - Basic earnings per share before issuance: 0.0383 yuan; after issuance: 0.0306 yuan - Weighted average return on net assets before issuance: 0.9549%; after issuance: 0.7574% [3][4] Necessity and Rationality of Financing - The financing is deemed necessary and rational as it supports projects that enhance the company's core competitiveness and sustainable development [5] - The company has established a full industrial chain in fluorine fine chemicals, with the new project aimed at expanding production capacity for specific products [6] Project Relationship and Resource Readiness - The fundraising projects are closely related to the company's existing business, leveraging its established market position and technological capabilities [6] - The company has a strong management team with extensive experience in the fine chemical industry, ensuring effective execution of the fundraising projects [7] Measures to Mitigate Dilution of Immediate Returns - The company will enhance governance structures to ensure sustainable development and protect shareholder rights [8] - Strict management of raised funds will be implemented to ensure proper usage and mitigate risks [8] - Continuous improvement in operational efficiency and profitability will be prioritized to counteract potential dilution effects [9] Commitments from Major Stakeholders - The controlling shareholders and management have committed to ensuring the effectiveness of measures to mitigate the dilution of immediate returns [10][11]

Corporate Presentation April 2025 1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadin (LX9211), LX9851, sotagliflozin ...

Core Insights - Cronos Group Inc. is expanding its distribution of the PEACE NATURALS medical cannabis brand in Switzerland through a partnership with Dascoli Pharma AG, a Swiss company specializing in medical cannabis supply and distribution [1][2] - The partnership aims to provide high-quality medical cannabis to Swiss patients and aligns with Cronos' mission to offer borderless cannabis products in European medical markets [2] - Cronos will supply PEACE NATURALS-branded cannabis flower to Dascoli for distribution across its established medical network in Switzerland, marking a significant step in Cronos' international growth strategy [2] Company Overview - Cronos Group Inc. is a global cannabinoid company focused on advancing cannabis research, technology, and product development, with a diverse international brand portfolio including Spinach, PEACE NATURALS, and Lord Jones [4] - The company is committed to building disruptive intellectual property and enhancing the consumer experience through its iconic brand portfolio [4] Partner Overview - Dascoli Pharma AG is a Swiss pharmaceutical firm that focuses on medical cannabis manufacturing and distribution across wholesale and retail channels, providing compliant cannabinoid therapies to patients, pharmacies, and clinics [5] - Dascoli is recognized as a leading cannabinoid retailer in Switzerland, offering next-day home delivery services for patients [5] Product Availability - PEACE NATURALS medical cannabis products are now available in multiple countries, including Australia, Canada, Germany, Israel, Malta, Switzerland, and the UK [3]

Showcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy for heart failure, powered by their proprietary human mini-Heart technology.FDA-backed human-based screening platform recognized as an animal-free alternative in drug development, supporting IND and Fast Track approvals under the FDA Modernization Act 2.0.Breakthroughs in high-throughput screening, AI-driven drug classification, and patient-specific disease modelling underscored the platform’s pote ...

Core Viewpoint - Zhejiang Xinhengtai New Materials Co., Ltd. has received IPO acceptance from the Beijing Stock Exchange, focusing on the research, manufacturing, and sales of functional polymer foam materials [1] Company Overview - Xinhengtai specializes in functional polymer foam materials, with main products including PEFoam, IXPE, and MPP, and has established itself as a strong supplier in China with good product quality and brand reputation [1] - The company has developed efficient preparation technologies for a range of foam materials and has set up production lines in Vietnam and Thailand to expand its production capacity [2] Product Applications - Xinhengtai's products are utilized by well-known flooring manufacturers such as Aili Home, Haixiang New Materials, and Cainafu [2] - In the MPP sector, the company holds a leading market share in the new energy battery cushioning market and 5G microwave antenna market, with applications in products from major brands like CATL, BYD, and Huawei [2] Recognition and Achievements - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise and has received multiple honors, including the Zhejiang Province Manufacturing Single Champion Cultivation Enterprise for 2024 [3] - Xinhengtai has established several research and development centers and has participated in drafting industry standards, holding 53 patents, including 21 invention patents [3] Financial Performance - The company's revenue for 2022, 2023, and 2024 was reported as 530.01 million yuan, 679.27 million yuan, and 774.22 million yuan, respectively, with net profits of 45.00 million yuan, 100.96 million yuan, and 91.76 million yuan [4] - The company aims to expand its applications into aerospace, semiconductors, biomedicine, and high-end equipment through its fundraising projects [4] Market Outlook - The Chinese polyethylene foam market is projected to grow from 1.976 billion USD in 2023 to 3.4 billion USD by 2028, with a compound annual growth rate of 9.04% from 2018 to 2023 [4] - The upcoming projects will address existing capacity bottlenecks, enhance market competitiveness, and promote green development [5]